Replimune vs Regeneron Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Replimune Group Inc (REPL)

Q3 202623 Jun – 11 Aug 2026

▲2▼2

FDA panel backs RP1, approval and offering reshape Replimune

FDA panel backs RP1 An FDA advisory panel voted 10-3 that RP1's single-arm IGNYTE data were clinically meaningful, reversing earlier doubts and sending shares up over 130% premarket; Wedbush upgraded the stock.
This was the key regulatory catalyst that drove the stock's massive jump.
Accelerated approval of Tudriqev The FDA granted accelerated approval to Tudriqev plus Opdivo for advanced melanoma (24.2% response rate), giving Replimune its first commercial product and revenue stream.
This approval is a major milestone that transforms the company's business prospects.
Securities fraud investigations Two law firms (Kirby McInerney, Bragar Eagel & Squire) and later Pomerantz opened securities fraud investigations into whether the company misled investors before the FDA's critical July 28 briefing documents.
These investigations pose a legal overhang that could weigh on the stock.
Dilutive stock offering A $150 million stock offering at $12.06/share issued ~9.7 million new shares, diluting existing holders.
The offering dilutes current shareholders and can pressure the share price.

July 202623 Jun – 11 Aug 2026

▲2▼2

FDA panel backs RP1, approval and offering reshape Replimune

FDA panel backs RP1 An FDA advisory panel voted 10-3 that RP1's single-arm IGNYTE data were clinically meaningful, reversing earlier doubts and sending shares up over 130% premarket; Wedbush upgraded the stock.
This was the key regulatory catalyst that drove the stock's massive jump.
Accelerated approval of Tudriqev The FDA granted accelerated approval to Tudriqev plus Opdivo for advanced melanoma (24.2% response rate), giving Replimune its first commercial product and revenue stream.
This approval is a major milestone that transforms the company's business prospects.
Securities fraud investigations Two law firms (Kirby McInerney, Bragar Eagel & Squire) and later Pomerantz opened securities fraud investigations into whether the company misled investors before the FDA's critical July 28 briefing documents.
These investigations pose a legal overhang that could weigh on the stock.
Dilutive stock offering A $150 million stock offering at $12.06/share issued ~9.7 million new shares, diluting existing holders.
The offering dilutes current shareholders and can pressure the share price.

Latest23 Jun – 11 Aug 2026

▲2▼2

FDA approves Replimune's first drug, then company raises $150M

FDA grants accelerated approval for Tudriqev The FDA granted accelerated approval to Replimune's Tudriqev combined with Opdivo for advanced melanoma, based on a 24.2% response rate. This is the company's first commercial product, turning it from a clinical-stage hopeful into a revenue-generating business and lifting the stock.
This is the single biggest new event: approval validates the drug and opens a path to sales.
Securities fraud investigation expands to Pomerantz Pomerantz LLP opened an investigation into whether Replimune misled investors before the FDA's July 28 briefing documents questioned the RP1 data. This adds to earlier law firm probes, keeping a legal cloud over the stock and potentially weighing on the price.
It is a new law firm joining the investigation, adding fresh negative pressure.
$150 million stock offering dilutes shareholders Replimune priced a $150 million stock sale at $12.06 per share, issuing about 9.7 million new shares. This raises cash to launch Tudriqev but dilutes existing investors' ownership, which typically pushes the stock down in the short term.
It is a new financing event that directly affects share count and cash position.
FDA flexibility and biotech rally support Replimune The FDA signaled a more flexible approval approach for serious diseases, opening new pathways for Replimune and others. This supportive regulatory backdrop helped biotech stocks broadly and made RP1's eventual approval more likely, lifting sentiment around Replimune.
It explains the favorable regulatory environment that helped Replimune's path to approval.

30 Jul – 31 Jul 2026

▲2▼1

FDA panel backs RP1, reversing prior briefing-document collapse

FDA advisory panel votes 10-3 in favor of RP1 An FDA advisory committee voted 10 to 3 that RP1's single-arm IGNYTE study results are evaluable and clinically meaningful for advanced melanoma. This removes the main regulatory doubt and makes approval by the August 2 target date far more likely, pushing the stock sharply higher.
This is the core new event that flipped sentiment and drove the huge price jump.
Stock surges over 130% premarket, analyst upgrade Replimune shares soared more than 130% before the open and were up about 94-125% during the day after the panel vote. Wedbush upgraded the stock to outperform from neutral, a sign that professional investors now see the approval path as much clearer.
Shows the market's immediate, large positive reaction and a key analyst endorsement.
Securities fraud investigations launched Two law firms, Kirby McInerney and Bragar Eagel & Squire, opened investigations into whether Replimune misled investors before the FDA's July 28 briefing documents called the RP1 study non-interpretable. No lawsuit has been filed yet, but this legal cloud could weigh on the stock.
A real counterweight that could hurt the stock even after the positive panel vote.

Regeneron Pharmaceuticals Inc (REGN)

Q3 20264 Jul – 1 Oct 2026

▲1▼1

Regeneron's Q3: Pipeline Wins, Melanoma Setback, Sanofi Deal

Q2 earnings beat with 17% revenue growth Regeneron's Q2 revenue rose 17% to $4.29 billion, beating estimates, driven by strong Dupixent and high-dose Eylea sales, while Sanofi repayment improved margins.
Strong financial results directly boost investor confidence and the stock price.
Failed melanoma trial triggers lawsuits and $11B value loss A failed melanoma trial led to securities lawsuits and wiped out $11 billion in market value, highlighting pipeline execution risks and disappointing investors.
This major setback significantly impacted Regeneron's market value and reputation.
Sanofi alliance expands with $1B upfront but Dupixent profit-sharing unchanged Sanofi's expanded alliance brought $1 billion upfront and up to $7 billion in milestones, but left Dupixent profit-sharing unchanged, causing shares to drop 4%.
The deal has both positive financial aspects and negative implications for Dupixent economics.

September 202617 Sep – 1 Oct 2026

▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.
This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.
Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.
A positive clinical readout in a major new market area is a key driver of future growth expectations.
Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.
Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.
Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.
It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

Latest17 Sep – 1 Oct 2026

▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.
This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.
Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.
A positive clinical readout in a major new market area is a key driver of future growth expectations.
Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.
Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.
Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.
It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

August 202627 Jul – 4 Sep 2026

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.
This is the period's biggest positive fundamental driver of REGN's value.
Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.
It is a concrete capital event that improves future profitability.
FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.
A new FDA approval is a fresh product and pipeline milestone for REGN.
Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.
This is the main negative overhang on REGN this period.

27 Jul – 4 Sep 2026

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.
This is the period's biggest positive fundamental driver of REGN's value.
Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.
It is a concrete capital event that improves future profitability.
FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.
A new FDA approval is a fresh product and pipeline milestone for REGN.
Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.
This is the main negative overhang on REGN this period.

July 20264 Jul – 24 Jul 2026

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.
This is a new positive regulatory catalyst that could drive future revenue and investor optimism.
Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.
This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.
Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.
This new analyst commentary underscores pipeline challenges that could pressure the stock.

4 Jul – 24 Jul 2026

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.
This is a new positive regulatory catalyst that could drive future revenue and investor optimism.
Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.
This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.
Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.
This new analyst commentary underscores pipeline challenges that could pressure the stock.

Q2 202619 Jun – 25 Jun 2026

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.
This is a new deal that adds to Regeneron's pipeline and potential future earnings.
Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.
Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.
FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.
This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.
AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.
This is a new competitive threat that could impact Regeneron's key product, Dupixent.

June 202619 Jun – 25 Jun 2026

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.
This is a new deal that adds to Regeneron's pipeline and potential future earnings.
Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.
Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.
FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.
This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.
AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.
This is a new competitive threat that could impact Regeneron's key product, Dupixent.

19 Jun – 25 Jun 2026

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.
This is a new deal that adds to Regeneron's pipeline and potential future earnings.
Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.
Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.
FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.
This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.
AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.
This is a new competitive threat that could impact Regeneron's key product, Dupixent.